Preparations continue apace for Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) ahead of its clinical trial of POLB 001, a treatment for severe influenza.
In an update, it said it signed a contract for the production of the drug to good manufacturing (GMP) standards, so it has ample supplies ready for the upcoming challenge study.
In March, Poolbeg signed a clinical trial agreement with the Centre for Human Drug Research, which will assess the efficacy of POLB 001.
The asset is being developed to reduce the body's hyperinflammatory response to flu.
As such “POLB 001 has the potential to address several disease indications beyond severe influenza”, pointed out chief executive Jeremy Skillington.
Poolbeg’s aim is to find a partner for its drug candidate early in its clinical development.